Holen Sie sich die Stockscreener-App
122.86
3.29%
-4.215
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Revvity Inc Aktie (RVTY) Neueste Nachrichten
RVTY Assumes Rating by UBS -- Price Target Raised to $140 - GuruFocus
Revvity Acquiring French Firm Human Cell Design - GenomeWeb
Revvity at Wells Fargo 21st annual healthcare conference: growth and margin focus - Investing.com Canada
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition - Benzinga
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery - BioSpace
RVTY Looks 8.1% Overvalued on GF Value™ - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow - GuruFocus
Revvity to Acquire Human Cell Design - marketscreener.com
Revvity to acquire Human Cell Design - TradingView
Revvity to acquire Human Cell Design for metabolic research tools - Investing.com
Revvity to acquire Human Cell Design for metabolic research tools By Investing.com - Investing.com Canada
A planned Revvity deal would add human pancreatic cells for diabetes research - Stock Titan
Revvity Inc. stock slips despite solid Q2 2026 growth and cautious analyst outlook - AD HOC NEWS
Revvity stock heads into the open after a 2.1 percent drop - AD HOC NEWS
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
T. Rowe Price controls over 10M Revvity (NYSE: RVTY) shares, with one fund holding about half the stake - Stock Titan
Revvity Inc. stock holds above 130 dollars as analysts stick with Hold ratings - AD HOC NEWS
Revvity, Inc. (RVTY) Stock Analysis: Navigating Potential in the Diagnostics Sector Amid Mixed Ratings - DirectorsTalk Interviews
KeyBanc Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? - Eastern Progress
KeyBanc Adjusts Price Target on Revvity to $165 From $125, Maintains Overweight Rating - marketscreener.com
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Revvity Inc. stock holds near 52-week high as valuation debate intensifies - AD HOC NEWS
Baird Adjusts Price Target on Revvity to $144 From $131, Keeps Outperform Rating - marketscreener.com
Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings - Yahoo Finance
Revvity Inc (RVTY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade - Yahoo Finance
What Makes Revvity (RVTY) a New Buy Stock - Yahoo Finance
Revvity Faces Growth Challenges Amid Rising Competition, RBC Says - marketscreener.com
RBC Initiates Revvity at Sector Perform With $135 Price Target - marketscreener.com
RBC Capital initiates Revvity stock with Sector Perform rating By Investing.com - Investing.com Australia
RBC Capital initiates Revvity stock with Sector Perform rating - Investing.com
Revvity, Inc. (RVTY) Stock Analysis: Navigating a 6% Potential Downside with Strategic Insights - DirectorsTalk Interviews
Revvity (RVTY) Eases to $128.8: Key Support at $122.36 Holds in FocusImbalance Zone - vinanet.vn
Revvity Inc stock hits 52-week high at 130.07 USD By Investing.com - Investing.com Nigeria
Revvity Inc stock hits 52-week high at 130.07 USD - Investing.com
Revvity (NYSE: RVTY) director donates 285 shares in stock gift - Stock Titan
Revvity, Inc. (RVTY) Stock Analysis: Healthcare Innovator With Mixed Growth Signals - DirectorsTalk Interviews
Revvity stock trades around $123 as investors weigh latest earnings and analyst targets - Ad-hoc-news.de
Why Revvity (RVTY) Stock Is Up Today - Quiver Quantitative
Revvity stock hits new 52-week high as gains extend - Ad-hoc-news.de
Revvity stock hits 52-week high at 122.26 USD - Investing.com
Revvity stock hits 52-week high at 122.26 USD By Investing.com - Investing.com India
Revvity Inc (RVTY) Shares Surge 5.0% -- What GF Score of 78 Tells Investors - GuruFocus
Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Revvity stock edges lower as SuperFlex launch and Q2 earnings shape valuation debate - Ad-hoc-news.de
Revvity Inc (RVTY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revvity (NYSE: RVTY) executive gifts 27,785 shares to trust - Stock Titan
Revvity (NYSE:RVTY) Gains Attention After SuperFlex Launch - Kalkine Media
Revvity CEO Prahlad Singh Transfers Over 67,000 Shares to Family Trusts in Gift Transactions - Kalkine Media
Revvity (NYSE: RVTY) CEO shifts stock into family trusts at $0 - Stock Titan
Revvity, Inc. (RVTY) Stock Analysis: A Healthcare Innovator with Modest Upside and Resilient Performance - DirectorsTalk Interviews
Revvity (NYSE:RVTY) Downgraded by Wall Street Zen to "Hold" - MarketBeat
T. Rowe Price (RVTY) reports 16.4% Revvity stake, 18.3M shares under control - Stock Titan
T. Rowe Price Associates (RVTY) discloses 5.0% beneficial stake in Revvity - Stock Titan
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs - Zacks Investment Research
Revvity (NYSE:RVTY) Hits New 12-Month HighWhat's Next? - MarketBeat
Revvyty Inc stock hits 52-week high at 118.34 USD By Investing.com - Investing.com South Africa
Revvity Inc. (NYSE:RVTY) Given Average Recommendation of "Hold" by Analysts - MarketBeat
The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call - Yahoo Finance
Revvity, Inc. (RVTY) Stock Forecasts - Yahoo Finance
Understanding the Setup: (RVTY) and Scalable Risk - Stock Traders Daily
1.84%
1.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):